CKAP5 Antikörper (AA 1-221)
-
- Target Alle CKAP5 Antikörper anzeigen
- CKAP5 (Cytoskeleton Associated Protein 5 (CKAP5))
-
Bindungsspezifität
- AA 1-221
-
Reaktivität
- Human, Maus, Ratte
-
Wirt
- Kaninchen
-
Klonalität
- Polyklonal
-
Konjugat
- Dieser CKAP5 Antikörper ist unkonjugiert
-
Applikation
- Western Blotting (WB), ELISA, Immunofluorescence (IF), Immunohistochemistry (IHC), Flow Cytometry (FACS), Immunocytochemistry (ICC)
- Verwendungszweck
- Anti-ch TOG/CKAP5 Antibody Picoband®
- Kreuzreaktivität (Details)
- No cross-reactivity with other proteins.
- Produktmerkmale
- Anti-ch TOG/CKAP5 Antibody Picoband® (ABIN6719294). Tested in ELISA, Flow Cytometry, IF, IHC, ICC, WB applications. This antibody reacts with Human, Mouse, Rat. The brand Picoband indicates this is a premium antibody that guarantees superior quality, high affinity, and strong signals with minimal background in Western blot applications. Only our best-performing antibodies are designated as Picoband, ensuring unmatched performance.
- Aufreinigung
- Immunogen affinity purified.
- Immunogen
- E.coli-derived human ch TOG/CKAP5 recombinant protein (Position: M1-L221).
- Isotyp
- IgG
- Top Product
- Discover our top product CKAP5 Primärantikörper
-
-
- Applikationshinweise
-
Western blot, 0.1-0.5 μg/mL, Human, Mouse, Rat
Immunohistochemistry (Paraffin-embedded Section), 2-5 μg/mL, Human, Mouse, Rat
Immunocytochemistry/Immunofluorescence, 5 μg/mL, Human
Flow Cytometry (Fixed), 1-3 μg/1x106 cells, Human
ELISA, 0.1-0.5 μg/mL, -
1. "Entrez Gene: CKAP5 cytoskeleton associated protein 5". 2. Charrasse S, Mazel M, Taviaux S, Berta P, Chow T, Larroque C (Feb 1996). "Characterization of the cDNA and pattern of expression of a new gene over-expressed in human hepatomas and colonic tumors". Eur. J. Biochem. 234 (2): 406-13. - Kommentare
-
Tested Species: In-house tested species with positive results. By Heat: Boiling the paraffin sections in 10mM citrate buffer, pH6.0, for 20mins is required for the staining of formalin/paraffin sections. Other applications have not been tested. Optimal dilutions should be determined by end users.
- Beschränkungen
- Nur für Forschungszwecke einsetzbar
-
- Format
- Lyophilized
- Rekonstitution
- Add 0.2 mL of distilled water will yield a concentration of 500 μg/mL.
- Konzentration
- 500 μg/mL
- Buffer
- Each vial contains 4 mg Trehalose, 0.9 mg NaCl and 0.2 mg Na2HPO4.
- Lagerung
- 4 °C,-20 °C
- Informationen zur Lagerung
-
Store at -20°C for one year from date of receipt. After reconstitution, at 4°C for one month.
It can also be aliquotted and stored frozen at -20°C for six months. Avoid repeated freeze-thaw cycles.
-
- Target
- CKAP5 (Cytoskeleton Associated Protein 5 (CKAP5))
- Andere Bezeichnung
- CKAP5 (CKAP5 Produkte)
- Hintergrund
-
Synonyms: Cytoskeleton-associated protein 5, Colonic and hepatic tumor overexpressed gene protein, Ch-TOG, CKAP5, KIAA0097
Tissue Specificity: Overexpressed in hepatomas and colonic tumors. Also expressed in skeletal muscle, brain, heart, placenta, lung, liver, kidney and pancreas. Expression is elevated in the brain, highly expressed in the Purkinje cell bodies of the cerebellum.
Background: Cytoskeleton-associated protein 5 is a microtubule-associated protein that in humans is encoded by the CKAP5 gene. It is mapped to 11p11.2. This gene encodes a cytoskeleton-associated protein which belongs to the TOG/XMAP215 family. The N-terminal half of this protein contains a microtubule-binding domain and the C-terminal half contains a KXGS motif for binding tubulin dimers. This protein has two distinct roles in spindle formation, it protects kinetochore microtubules from depolymerization and plays an essential role in centrosomal microtubule assembly. This protein may be necessary for the proper interaction of microtubules with the cell cortex for ional cell movement. It also plays a role in translation of the myelin basic protein (MBP) mRNA by interact ernatively spliced transcript variants encoding different isoforms have been identified.
- Molekulargewicht
- 225 kDa
- Gen-ID
- 9793
- UniProt
- Q14008
- Pathways
- M Phase
-